A cancer diagnosis can bring urgent decisions about surgery, chemotherapy, radiation therapy, and long-term recovery. For younger patients, however, another important concern may be how treatment could affect their ability to have biological children in the future. Oncofertility combines cancer care with reproductive medicine, helping patients understand fertility risks and consider preservation options before treatment begins. The cost of fertility preservation and the possibility of an expensive reproductive procedure can add financial pressure during an already difficult period. Early counselling gives patients an opportunity to discuss their priorities, understand available choices, and make informed decisions without unnecessarily delaying essential cancer treatment.
Understanding Oncofertility and Its Role in Cancer Care
Oncofertility is a specialist field that connects oncology, reproductive endocrinology, embryology, and fertility preservation. Its purpose is to protect reproductive options for people whose cancer treatment may affect the ovaries, testes, reproductive organs, or hormonal systems.
Some cancer treatments can damage eggs, sperm, or the tissues responsible for producing them. The degree of risk depends on the patient’s age, diagnosis, treatment type, medication dosage, radiation exposure, and previous reproductive health. Certain treatments may cause temporary changes, while others can lead to long-term or permanent infertility.
Fertility preservation is not necessary or appropriate for every patient. Some individuals may already have completed family planning, while others may prefer to focus exclusively on cancer treatment. The decision is personal and should be supported by accurate medical information rather than pressure or assumptions.
How Cancer Treatment Can Affect Reproductive Health
Chemotherapy can affect rapidly dividing cells, including developing reproductive cells. Some chemotherapy medicines are more likely than others to damage ovarian follicles or reduce sperm production. The impact may depend on cumulative exposure, treatment combinations, and the patient’s age when therapy begins.
Radiation therapy can also affect fertility when reproductive organs or nearby structures receive significant exposure. Pelvic radiation may damage ovarian tissue, the uterus, or the testes. Radiation involving the brain can sometimes affect hormonal signals that regulate reproductive function.
Surgery may influence fertility when it involves removal of reproductive organs or tissues. For example, treatment for certain gynecological cancers may require removal of the uterus or ovaries. In selected cases, fertility-sparing surgery may be considered, but only when it is medically appropriate and does not compromise cancer control.
Hormone therapies and targeted cancer medicines may also influence reproductive function. Their effects vary, and some treatments require temporary interruption of attempts to conceive. Patients should ask their oncology team how long pregnancy should be avoided and whether a washout period is required after treatment.
Who Should Consider Fertility Preservation?
Fertility counselling should be offered to patients of reproductive potential when cancer treatment may affect their future ability to conceive. This includes adolescents, young adults, and older patients who have not completed their family plans. The conversation should happen as early as practical, ideally before chemotherapy, radiation, or reproductive surgery begins.
People diagnosed with breast cancer, lymphoma, leukemia, testicular cancer, cervical cancer, and other malignancies may benefit from an individualized assessment. The level of risk is not identical across these diagnoses. The planned treatment regimen is often more important than the cancer name alone.
Age is a major consideration because ovarian reserve and egg quality generally change over time. A patient’s medical condition, reproductive history, family circumstances, and personal preferences also influence which options are realistic. A fertility specialist can explain the likely benefits and limitations without promising a future pregnancy.
Egg and Embryo Cryopreservation
Egg freezing, also known as oocyte cryopreservation, is an established fertility preservation method. The process generally involves ovarian stimulation using prescribed hormonal medicines, followed by ultrasound and blood-test monitoring. When the eggs reach an appropriate stage, they are collected through a medical procedure and frozen for potential future use.
Embryo cryopreservation follows a similar stimulation and egg collection process, but the eggs are fertilized with sperm in an embryology laboratory before freezing. The resulting embryos can be stored for future reproductive treatment. This option may be suitable for patients who have a partner or choose donor sperm, depending on local laws and personal circumstances.
Neither approach guarantees a future live birth. The number and quality of eggs or embryos, the patient’s age at preservation, laboratory performance, and future medical circumstances all influence outcomes. Patients should receive realistic counselling about success rates and the possibility that more than one preservation cycle may be needed.
Sperm Banking and Male Fertility Preservation
Sperm cryopreservation is commonly offered to males who may receive treatment that could impair sperm production. A semen sample is collected and assessed before being frozen for future use. Stored sperm may later be used in assisted reproductive procedures, depending on sample quality and the patient’s reproductive needs.
When a patient cannot provide a sample through standard collection, a fertility specialist may discuss alternative approaches. In selected cases, sperm retrieval procedures can be considered. For adolescents who have not reached puberty, established sperm banking may not be possible, so specialist advice is essential.
Patients should ask how many samples are recommended, how long storage is available, what annual fees apply, and what happens if they move to another clinic. Confidentiality and consent arrangements should also be explained clearly.
Ovarian Tissue and Other Preservation Approaches
Ovarian tissue cryopreservation involves surgically removing and freezing a portion of ovarian tissue for possible future use. It may be considered when there is insufficient time for ovarian stimulation or when stimulation is not medically suitable. The technique can be particularly relevant for selected patients who need urgent cancer treatment, although eligibility depends on diagnosis and the risk of cancer cells being present in the tissue.
Ovarian transposition is another option for some patients receiving pelvic radiation. A surgeon moves the ovaries away from the planned radiation field when anatomy and treatment objectives permit. This may reduce radiation exposure, but it does not eliminate every risk and may not protect against damage from chemotherapy.
For certain patients, medical treatment aimed at temporarily suppressing ovarian activity during chemotherapy may be discussed. It should not be considered a guaranteed substitute for established fertility preservation methods. The oncology and reproductive teams should explain the available evidence and whether the approach is suitable for the specific cancer.
Fertility Assessment Before Treatment
A pre-treatment consultation usually includes a review of the cancer diagnosis, proposed treatment schedule, reproductive goals, and relevant medical history. Patients may undergo hormone testing, pelvic ultrasound, semen analysis, or other investigations depending on their circumstances. Tests such as anti-Müllerian hormone can provide information about ovarian reserve, but they cannot independently predict whether a person will achieve pregnancy in the future.
The fertility specialist should coordinate closely with the oncologist. Some preservation methods require time for appointments, medication, monitoring, or procedures. The team must balance these requirements against the urgency of cancer treatment. In many situations, preservation can be arranged within a limited timeframe, but treatment for an aggressive or rapidly progressing cancer should not be delayed without a clear medical decision.
Patients should receive written information about the procedure, possible complications, storage arrangements, future treatment requirements, and the likelihood that stored reproductive material may never be used. Informed consent is particularly important when decisions are being made during emotional distress.
Emotional Support and Family Planning
Fertility concerns can affect emotional well-being, relationships, and a patient’s sense of control during cancer treatment. Some people feel distressed about the possibility of losing reproductive options, while others are uncertain about whether they want children. Both responses deserve respect.
Oncology social workers, psychologists, fertility counsellors, and support organizations can help patients discuss difficult decisions. Partners and family members may participate when the patient wishes, but the final decision should remain consistent with the patient’s preferences and applicable consent requirements.
For children and adolescents, counselling requires additional care. Discussions should be age-appropriate and involve parents or guardians according to legal requirements, while respecting the young person’s developing understanding and preferences.
Estimated Expenses for Fertility Preservation
Prices differ considerably between countries, fertility centres, medication protocols, laboratory facilities, and storage providers. The following figures are illustrative estimates in US dollars. They are not official quotations and may not include every hospital, medication, laboratory, or professional charge.
| Fertility Service | Estimated Amount (USD) |
|---|---|
| Initial reproductive specialist consultation | $100–$300 |
| Ovarian reserve testing and ultrasound | $150–$450 |
| Ovarian stimulation medication | $1,500–$5,000 |
| Egg retrieval and laboratory processing | $3,000–$7,000 |
| Embryo freezing procedure | $1,000–$3,000 |
| Sperm collection and cryopreservation | $300–$1,000 |
| Initial reproductive material storage | $300–$800 |
Some clinics offer packages that combine consultation, monitoring, egg collection, and laboratory services. Medication may be billed separately, and additional testing can increase the final amount. Patients should request a written breakdown before starting a cycle and confirm whether cancellation, repeat collection, or extended storage creates additional charges.
Long-Term Storage and Future Reproductive Treatment
Preserving eggs, embryos, sperm, or tissue is only one stage of the process. Patients may later need fertility treatment to use the stored material. Depending on the preservation method, this may involve thawing, laboratory fertilization, embryo transfer, or other assisted reproductive procedures.
Future treatment may not be medically appropriate immediately after cancer therapy. The oncology team must assess recovery, recurrence risk, current medicines, and the safety of pregnancy. Some patients may need to wait for a recommended period before attempting conception. Others may be advised against pregnancy because of their particular medical circumstances.
Storage contracts should clearly explain annual charges, renewal dates, consent requirements, and the process for transferring material to another facility. Patients should also understand the clinic’s policies if they become unable to maintain payments or change their reproductive plans.
| Additional Service or Procedure | Estimated Amount (USD) |
|---|---|
| Annual egg or embryo storage | $300–$800 |
| Annual sperm storage | $150–$500 |
| Frozen embryo transfer cycle | $2,000–$5,000 |
| In vitro fertilization treatment cycle | $8,000–$15,000 |
| Embryology laboratory services | $1,000–$3,000 |
| Ovarian tissue preservation procedure | $5,000–$10,000 |
| Specialist follow-up consultation | $100–$300 |
| Psychological fertility counselling | $75–$200 |
These figures represent possible future services and should not be treated as a single required package. A patient who stores sperm may not need ovarian stimulation or embryo transfer, while another person may require several stages of assisted reproductive care. Travel, accommodation, medication, and repeat consultations can also affect the overall financial plan.
Insurance Coverage and Choosing a Fertility Centre
Insurance coverage for fertility preservation varies by country, policy, cancer diagnosis, and the reason treatment may affect reproductive function. Some insurers provide benefits for medically indicated preservation, while others exclude storage or assisted reproduction. Patients should ask the insurer for written confirmation of eligible services, reimbursement limits, network requirements, and authorization procedures.
When comparing fertility centres, patients should review laboratory accreditation, embryology experience, storage security, clinical success reporting, and coordination with oncology services. A centre should explain its preservation methods and limitations clearly rather than making unrealistic promises. It should also provide a transparent financial estimate and a reliable process for future communication.
Conclusion
Oncofertility preservation gives people facing cancer treatment an opportunity to consider their future reproductive goals before medical therapy begins. Egg freezing, embryo banking, sperm cryopreservation, ovarian tissue preservation, and other selected approaches may help protect future choices, although none guarantees a successful pregnancy. Patients should discuss the expected cost and potentially expensive procedures with qualified oncology and fertility specialists, while checking insurance benefits and long-term storage arrangements. Early counselling, realistic information, and coordinated medical care can help individuals make decisions that respect both their cancer treatment priorities and their hopes for the future.